DR. MARTIN BERT LEON, M.D.
Osteopathic Medicine at Fort Washington Ave, New York, NY

2006005, Mar 16, 2006

Sep 7, 2005

11/221469

Ran Kornowski - Ramat-Hasharon, IL
Shmuel Fuchs - Rockville MD, US
Stephen Epstein - Rockville MD, US
Martin Leon - New York NY, US

MYOCARDIAL THERAPEUTICS, INC. - La Jolla CA

C12N 5/08

435372000, 514044000

A therapeutic composition is provided that comprises a cell-free conditioned medium containing mixed secretion products of isolated angiogenic progenitor cells obtained from bone marrow, peripheral blood, or adipose tissue. The composition may additionally contain angiogenesis-promoting proteins obtained by transfecting the progenitors cells in culture with an angiogenesis promoting transgene. The composition is useful to promote angiogenesis when introduced into or adjacent to an ischemic site in a patient, such as in myocardium or peripheral limb. Methods are also provided for utilizing such cell-free conditioned medium to deliver angiogenesis-promoting proteins to a patient. The cell-free conditioned medium can also be injected into the blood stream for delivery to the ischemic tissue. The cells can derive from either an autologous or allogenic source and can be lyophilized or frozen for storage.

7918884, Apr 5, 2011

Jun 8, 2004

10/863192

David C. Majercak - Stewartsville NJ, US
Matthew Krever - Warren NJ, US
Jin S. Park - Parsippany NJ, US
Robert S. Burgermeister - Bridgewater NJ, US
Hikmat Hojeibane - Princeton NJ, US
Martin B. Leon - New York NY, US

Cordis Corporation - Bridgewater NJ

A61F 2/01

623 115

A stent includes a lattice defining a substantially cylindrical configuration having a proximal end portion and a distal end portion, and a middle portion between the proximal end and the distal end. The lattice being moveable from a crimped state to an expanded state, and a plurality of adjacent hoops. Each hoop has a plurality of adjacent loops. Additionally, the stent further includes a plurality of bridges connecting adjacent hoops and a plurality of extensions on the lattice. Each of the hoops and bridges define a cell. The proximal end portion and the distal end portion of the lattice have at least one cell respectively and the middle portion of the lattice has at least one cell. The plurality of extensions are on the middle portion of the lattice. The plurality of extensions are cantilevered projections from the bridges and/or hoops of the lattice. The plurality of extensions are movably deformable in a direction away from the lattice, for example, at least some of the extensions are movably deformable in a direction away from the bridges and at least some of the extensions are movably deformable in a direction away from the hoops.

2006005, Mar 9, 2006

Apr 27, 2005

11/117607

Ran Kornowski - Ramat-Hasharon, IL
Shmuel Fuchs - Rockville MD, US
Stephen Epstein - Rockville MD, US
Martin Leon - New York NY, US

MYOCARDIAL THERAPEUTICS, INC. - La Jolla CA

A61K 48/00

424093210, 514044000

Methods are provided for promoting formation of collateral blood supply at an ischemic site in tissue by culturing early attaching cells derived from growth of bone marrow aspirate in vitro, collecting early attaching cells produced by the bone marrow culture and injecting conditioned medium produced by culture of the early attaching cells into an ischemic site in heart or limb. The preferred early attaching cells for use in the invention methods are marrow-derived stromal cells. Any donor's bone marrow can be used in preparation of the conditioned medium. Optionally, the early attaching cells can be transfected with an angiogenesis promoting transgene encoding hypoxia inducing factor 1 alpha, a fibroblast growth factor and/or a nitric oxide synthase. Conditioned media containing angiogenic cytokines produced such cells are also provided for injection into tissue, such as heart or peripheral limb muscle, requiring formation of collateral blood supply.

2003003, Feb 27, 2003

Sep 30, 2002

10/260954

Gishel New - New York NY, US
Jeffrey Moses - New York NY, US
Nicholas Kipshidze - New York NY, US
Gary Roubin - New York NY, US
Martin Leon - New York NY, US

ESTROGEN VASCULAR TECHNOLOGY, LLC.

A61K031/56, A61F002/00

424/423000, 514/182000, 514/178000

A method of treating or preventing vascular disease in a living organism. The method includes delivering an effective amount of a composition including a sex hormone, anti-hormone, sex-hormone agonist, steroid-hormone inhibitor/antagonist (partial or full), selective estrogen receptor modulator (SERM), or a combination thereof, to an affected area of a living organism.

2002007, Jun 13, 2002

Aug 30, 2001

09/943648

Gishel New - New York NY, US
Jeffrey Moses - New York NY, US
Nicholas Kipshidze - New York NY, US
Gary Roubin - New York NY, US
Martin Leon - New York NY, US

A61K031/56, A61F002/06, A61K031/685

514/182000, 623/001150, 514/078000, 514/178000

A method of treating or preventing vascular disease in a living organism. The method includes delivering an effective amount of a composition including a sex hormone, anti-hormone, sex-hormone agonist, steroid-hormone inhibitor/antagonist (partial or full), selective estrogen receptor modulator (SERM), or a combination thereof, to an affected area of a living organism.

7107997, Sep 19, 2006

Sep 9, 2002

10/383785

Jeffrey Warren Moses - New York NY, US
Nicholas N. Kipshidze - New York NY, US
Martin B. Leon - New York NY, US
Ran Kornowski - Ramat Hasharon, 47314, IL

A61B 19/00

128898, 606 7, 606 9, 607 88, 607 89

The present invention relates to methods and apparatuses for use in revascularization of damaged areas of myocardium through application of one or more radiation type treatment modalities.